Stifel Nicolaus Forecasts Strong Price Appreciation for OptimizeRx (NASDAQ:OPRX) Stock

Key Points

• Stifel Nicolaus has raised the price target for OptimizeRx (NASDAQ:OPRX) from $16.00 to $18.00, indicating a potential upside of 5.16%.
• Shares of OptimizeRx saw a significant increase, trading up 33.3% to reach $17.12, while the stock's 1-year high is $18.22.
• Most analysts maintain a positive outlook on OptimizeRx, with three rating it as a hold and nine assigning a buy rating, leading to an average rating of "Moderate Buy".

OptimizeRx (NASDAQ:OPRX - Get Free Report) had its price target increased by Stifel Nicolaus from $16.00 to $18.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Stifel Nicolaus' target price would indicate a potential upside of 5.16% from the stock's previous close.

OPRX has been the topic of a number of other research reports. Wall Street Zen upgraded shares of OptimizeRx from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. JMP Securities raised their price objective on OptimizeRx from $11.00 to $14.00 and gave the stock a "market outperform" rating in a report on Tuesday, May 13th. Roth Capital reissued a "buy" rating on shares of OptimizeRx in a research report on Friday. B. Riley reaffirmed a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Finally, Citigroup reissued an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $11.06.

OptimizeRx Trading Up 33.3%

Shares of OPRX traded up $4.28 on Friday, hitting $17.12. 1,252,387 shares of the stock traded hands, compared to its average volume of 372,928. OptimizeRx has a 1 year low of $3.78 and a 1 year high of $18.22. The stock's 50 day moving average is $13.41 and its two-hundred day moving average is $9.75. The firm has a market capitalization of $316.66 million, a P/E ratio of -20.02, a P/E/G ratio of 4.16 and a beta of 1.33. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 0.25.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.19. The business had revenue of $21.93 million during the quarter, compared to the consensus estimate of $18.69 million. OptimizeRx had a negative return on equity of 0.29% and a negative net margin of 16.33%. As a group, sell-side analysts predict that OptimizeRx will post -0.33 earnings per share for the current year.

Institutional Trading of OptimizeRx

Institutional investors and hedge funds have recently bought and sold shares of the company. Whetstone Capital Advisors LLC increased its holdings in shares of OptimizeRx by 11.7% in the 1st quarter. Whetstone Capital Advisors LLC now owns 1,508,303 shares of the company's stock valued at $13,062,000 after acquiring an additional 157,880 shares during the last quarter. Blair William & Co. IL increased its stake in OptimizeRx by 4.9% during the first quarter. Blair William & Co. IL now owns 631,031 shares of the company's stock valued at $5,465,000 after purchasing an additional 29,648 shares during the last quarter. Kennedy Capital Management LLC raised its holdings in shares of OptimizeRx by 57.8% during the fourth quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock worth $2,887,000 after purchasing an additional 217,676 shares during the period. Parkman Healthcare Partners LLC bought a new position in shares of OptimizeRx in the 1st quarter worth about $4,114,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of OptimizeRx by 9.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company's stock valued at $2,159,000 after buying an additional 39,740 shares during the period. Institutional investors and hedge funds own 76.47% of the company's stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.